so the new integrase from GSK-ViiV is recruiting in phase III...

so the new integrase from GSK-ViiV is recruiting in phase III trials...

"Based on findings to date, twice-daily dosing has been chosen for forthcoming Phase 3 trials.."

and you guessed it, 150 patient planned recruitment...

TWICE daily and 150 pts...!

i thought they all had to do 'at least 900 pts' and twice daily was not competitive...lmao
be careful what u read there are fools out there!

http://clinicaltrials.gov/ct2/show/NCT01328041?term=dolutegravir&rank=1

http://www.gsk-clinicalstudyregister.com/protocol_detail.jsp?protocolId=112574&studyId=167F6DC6-A6E6-4D94-B674-5475D4538518&compound=dolutegravir&type=Compound&letterrange=A-F